Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis

Human cytomegalovirus can cause a diverse range of diseases in different immunocompromised hosts. The pathogenic mechanisms underlying these diseases have not been fully elucidated, though the maximal viral load during infection is strongly correlated with the disease. However, concentrating on single viral load measures during infection ignores valuable information contained during the entire replication history up to the onset of disease. We use a statistical model that allows all viral load data sampled during infection to be analysed, and have applied it to four immunocompromised groups exhibiting five distinct cytomegalovirus-related diseases. The results show that for all diseases, peaks in viral load contribute less to disease progression than phases of low virus load with equal amount of viral turnover. The model accurately predicted the time of disease onset for fever, gastrointestinal disease and pneumonitis but not for hepatitis and retinitis, implying that other factors may be involved in the pathology of these diseases.

[1]  Louis J. Picker,et al.  Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects , 2005, The Journal of experimental medicine.

[2]  G. Carcelain,et al.  Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease , 2005, The Journal of experimental medicine.

[3]  R. Hetzer,et al.  Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells , 2005, The Journal of experimental medicine.

[4]  D. Baarle,et al.  Progression to CMV end-organ disease in HIV-1-infected individuals despite abundance of highly differentiated CMV-specific CD8+ T-cells. , 2005, Immunology letters.

[5]  F. Miedema,et al.  Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. , 2005, The Journal of infectious diseases.

[6]  C. Sabin,et al.  Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy , 2004, The Lancet.

[7]  H. Ploegh,et al.  A membrane protein required for dislocation of misfolded proteins from the ER , 2004, Nature.

[8]  E. Mocarski Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. , 2002, Trends in microbiology.

[9]  H. Ploegh,et al.  The Human Cytomegalovirus US8 Glycoprotein Binds to Major Histocompatibility Complex Class I Products , 2002, Journal of Virology.

[10]  Andrew K Burroughs,et al.  Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. , 2002, The Journal of infectious diseases.

[11]  H. Ploegh,et al.  Human Cytomegalovirus Gene Products US2 and US11 Differ in Their Ability To Attack Major Histocompatibility Class I Heavy Chains in Dendritic Cells , 2002, Journal of Virology.

[12]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Richman,et al.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.

[14]  S. Staprans,et al.  Contribution of Peaks of Virus Load to Simian Immunodeficiency Virus Pathogenesis , 2002, Journal of Virology.

[15]  H. Ploegh,et al.  Human Cytomegalovirus Open Reading Frame TRL11/IRL11 Encodes an Immunoglobulin G Fc-Binding Protein , 2001, Journal of Virology.

[16]  L. Schmetterer,et al.  Ocular blood flow in patients infected with human immunodeficiency virus. , 2001, American journal of ophthalmology.

[17]  W. Cumberland,et al.  Decreased macular leukocyte velocity in human immunodeficiency virus-infected individuals. , 2001, American journal of ophthalmology.

[18]  R. Laufs,et al.  Area under the viraemia curve versus absolute viral load: Utility for predicting symptomatic cytomegalovirus infections in kidney transplant patients , 2001, Journal of medical virology.

[19]  V. Emery,et al.  Investigation of CMV disease in immunocompromised patients , 2001, Journal of clinical pathology.

[20]  A. Limaye,et al.  Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. , 2001, The Journal of infectious diseases.

[21]  G. Janossy,et al.  Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited , 2000, Bone Marrow Transplantation.

[22]  J. Bell,et al.  Functional Heterogeneity and High Frequencies of Cytomegalovirus-Specific CD8+ T Lymphocytes in Healthy Seropositive Donors , 2000, Journal of Virology.

[23]  C. Sabin,et al.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation , 2000, The Lancet.

[24]  W. G. Nichols,et al.  Recent advances in the therapy and prevention of CMV infections. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[25]  C. Sabin,et al.  Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group , 1999, The Journal of infectious diseases.

[26]  Vincent C. Emery,et al.  The Dynamics of Human Cytomegalovirus Replication in Vivo , 1999, The Journal of experimental medicine.

[27]  C. Sabin,et al.  Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG) , 1999, Journal of medical virology.

[28]  A. Minguela,et al.  Effect of partial HLA class I match on acute rejection in viral pre-infected human liver allograft recipients. , 1998, Transplantation.

[29]  C. Sabin,et al.  Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease , 1998, Bone Marrow Transplantation.

[30]  S. Spector,et al.  Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. , 1998, The Journal of clinical investigation.

[31]  C. Sabin,et al.  Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. , 1997, The Journal of infectious diseases.

[32]  C. Sabin,et al.  Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV‐positive patients at high risk of CMV disease , 1997, AIDS.

[33]  F. Ognibene,et al.  Lack of clinical utility of bronchoalveolar lavage cultures for cytomegalovirus in HIV infection. , 1997, American journal of respiratory and critical care medicine.

[34]  S. Spector,et al.  Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. , 1997, The Journal of infectious diseases.

[35]  J. Phair,et al.  Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. , 1996, Archives of ophthalmology.

[36]  P. Griffiths,et al.  Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. , 1995, The Journal of general virology.

[37]  M. Ho Advances in understanding cytomegalovirus infection after transplantation. , 1994, Transplantation proceedings.

[38]  S. Riddell,et al.  Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes , 1994, Journal of medical virology.

[39]  P. Griffiths,et al.  Quantification of human cytomegalovirus DNA using the polymerase chain reaction. , 1992, The Journal of general virology.

[40]  P. Griffiths,et al.  Severe cytomegalovirus pneumonitis in HIV infected patients with higher than average CD4 counts. , 1992, Thorax.

[41]  T. Shenk,et al.  Manipulation of the cell cycle by human cytomegalovirus. , 2002, Frontiers in bioscience : a journal and virtual library.

[42]  H. Ploegh,et al.  Viral subversion of the immune system. , 2000, Annual review of immunology.

[43]  D. Jabs,et al.  Cytomegalovirus retinitis in AIDS: natural history, diagnosis, and treatment. , 1995, AIDS clinical review.